180 Life Sciences Adalimumab Study Publishes Positive IIb Dupuytren’s Disease Data

Company Has Started Initial Consultations With US And UK Regulators

 
• By Chloe Kent

Adalimumab could find itself with a tenth official indication, after 180 Life Sciences found that it was able to effectively treat nodule hardness and size in Dupuytren’s disease during a phase IIb study.

Hands of a patient with Dupuytren's disease
Dupuytren's disease currently has few treatment options. • Source: Shutterstock

More from Biosimilars

More from Products